Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: Am Karlsbad 15 / 10785 Berlin
Tel: +49 (0) 30 2639 2880
Cytolon is the first technology company to fulfill the central needs of personalized medicine. Personalized medicine is based on matching the patient´s personal genomic and histocompatibility data with the characteristics of a given product in order to achieve the best possible therapeutic effect. As medical treatments become more personalized, it will be increasingly important to be able to provide fast and accurate matching of patient data with therapeutic products for hundreds of thousands of patient cases at any time. A comprehensive solution can only be provided by intelligent internet-based matching platforms. As of today, there are no matching platforms that fulfill these needs. Cytolon was created to fill this gap.
Cytolon´s corporate mission is to be the world’s first trusted source for obtaining the correct, best-matched personalized product in a timely and cost-effective manner. Cytolon meets the requirements of personalized medicine through high performance matching, comprehensive logistics and secure data management for clinical development.
As allogeneic cord blood units and the stem cells contained within them are the first existing personalized products in clinical practice, Cytolon is initially focusing on this market. An accurate, timely matching process is imperative as a cord blood unit (CBU) must perfectly match the histocompatibility antigens and genetic needs of the patient and must be delivered within days.
Cytolon has developed a proprietary, patent-pending, global internet-based cord blood matching platform called CordMatch®. This platform is unique, as it integrates product search and matching, selection and logistics plus billing and follow-up.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
See our Cookie Privacy Policy Here